These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 39142831

  • 1. Single Chelator-Minibody Theranostic Agents for 89Zr PET Imaging and 177Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer.
    Ho KV, Tatum DS, Watkinson L, Carmack T, Jia F, Mascioni A, Maitz CA, Magda D, Anderson CJ.
    J Nucl Med; 2024 Sep 03; 65(9):1435-1442. PubMed ID: 39142831
    [Abstract] [Full Text] [Related]

  • 2. Design, synthesis, and preclinical evaluation of a novel bifunctional macrocyclic chelator for theranostics of cancers.
    Xu J, Cai F, Luo Z, Fan W, Dai J, Cui J, Li S, Geng C, Zheng Q, Wang Z, Tang X.
    Eur J Nucl Med Mol Imaging; 2022 Jul 03; 49(8):2618-2633. PubMed ID: 35347438
    [Abstract] [Full Text] [Related]

  • 3. Radiolabeling of PSMA-617 with 89Zr: A novel use of DMSO to improve radiochemical yield and preliminary small-animal PET results.
    Imura R, Ozeki AN, Shida N, Kobayashi M, Ida H, Wada Y, Akimitsu N, Kumakura Y.
    Nucl Med Biol; 2022 Jul 03; 106-107():21-28. PubMed ID: 34998216
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. 177Lu-Labeled Albumin-Binder-Conjugated PSMA-Targeting Agents with Extremely High Tumor Uptake and Enhanced Tumor-to-Kidney Absorbed Dose Ratio.
    Kuo HT, Lin KS, Zhang Z, Uribe CF, Merkens H, Zhang C, Bénard F.
    J Nucl Med; 2021 Apr 03; 62(4):521-527. PubMed ID: 32859704
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of a Radio-IMmunoStimulant (RIMS) in a Syngeneic Model of Murine Prostate Cancer and ImmunoPET Analysis of T-cell Distribution.
    Śmiłowicz D, Schlyer D, Boros E, Meimetis L.
    Mol Pharm; 2022 Sep 05; 19(9):3217-3227. PubMed ID: 35895995
    [Abstract] [Full Text] [Related]

  • 8. Enhancing Treatment Efficacy of 177Lu-PSMA-617 with the Conjugation of an Albumin-Binding Motif: Preclinical Dosimetry and Endoradiotherapy Studies.
    Kuo HT, Merkens H, Zhang Z, Uribe CF, Lau J, Zhang C, Colpo N, Lin KS, Bénard F.
    Mol Pharm; 2018 Nov 05; 15(11):5183-5191. PubMed ID: 30251544
    [Abstract] [Full Text] [Related]

  • 9. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of 68Ga3+, 111In3+, 177Lu3+ and 225Ac3.
    Kelly JM, Amor-Coarasa A, Nikolopoulou A, Kim D, Williams C, Vallabhajosula S, Babich JW.
    Nucl Med Biol; 2017 Dec 05; 55():38-46. PubMed ID: 29055836
    [Abstract] [Full Text] [Related]

  • 10. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
    Umbricht CA, Benešová M, Schibli R, Müller C.
    Mol Pharm; 2018 Jun 04; 15(6):2297-2306. PubMed ID: 29684274
    [Abstract] [Full Text] [Related]

  • 11. Novel [68Ga/177Lu]Ga/Lu-AZ-093 as PSMA-Targeting Agent for Diagnosis and Radiotherapy.
    Wang R, Jin W, Luo Y, Hong H, Zhao R, Li L, Yan L, Qiao J, Ploessl K, Zhu L, Kung HF.
    Mol Pharm; 2024 Jul 01; 21(7):3256-3267. PubMed ID: 38856975
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of 111In-DOTA-5D3, a Surrogate SPECT Imaging Agent for Radioimmunotherapy of Prostate-Specific Membrane Antigen.
    Banerjee SR, Kumar V, Lisok A, Plyku D, Nováková Z, Brummet M, Wharram B, Barinka C, Hobbs R, Pomper MG.
    J Nucl Med; 2019 Mar 01; 60(3):400-406. PubMed ID: 30237212
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. An Improved 211At-Labeled Agent for PSMA-Targeted α-Therapy.
    Mease RC, Kang CM, Kumar V, Banerjee SR, Minn I, Brummet M, Gabrielson KL, Feng Y, Park A, Kiess AP, Sgouros G, Vaidyanathan G, Zalutsky MR, Pomper MG.
    J Nucl Med; 2022 Feb 01; 63(2):259-267. PubMed ID: 34088772
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [177Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside.
    Arbuznikova D, Klotsotyra A, Uhlmann L, Domogalla LC, Steinacker N, Mix M, Niedermann G, Spohn SKB, Freitag MT, Grosu AL, Meyer PT, Gratzke C, Eder M, Zamboglou C, Eder AC.
    Theranostics; 2024 Feb 01; 14(6):2560-2572. PubMed ID: 38646643
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Preclinical Evaluation of 203/212Pb-Labeled Low-Molecular-Weight Compounds for Targeted Radiopharmaceutical Therapy of Prostate Cancer.
    Banerjee SR, Minn I, Kumar V, Josefsson A, Lisok A, Brummet M, Chen J, Kiess AP, Baidoo K, Brayton C, Mease RC, Brechbiel M, Sgouros G, Hobbs RF, Pomper MG.
    J Nucl Med; 2020 Jan 01; 61(1):80-88. PubMed ID: 31253744
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.